E3 ligase Ligand 2
(Synonyms: 2-(2,6-二氧代-哌啶-3-基)-4-羟基-异吲哚-1,3-二酮,Cereblon ligand 2; E3 ligase Ligand 2) 目录号 : GC32848
An active metabolite of thalidomide and a PROTAC synthetic intermediate
Cas No.:5054-59-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
E3 ligase ligand 2 is an active metabolite of thalidomide and an intermediate in the synthesis of proteolysis-targeting chimeras (PROTACs) containing thalidomide, a ligand for the E3 ubiquitin ligase cereblon (CRBN), used in targeted protein degradation.1,2 E3 ligase ligand 2 is formed from thalidomide via hydroxylation. It decreases the production of TNF-α induced by 12-O-tetradecanoylphorbol 13-acetate in THP-1 cells when used at a concentration of 30 ?M.3 E3 ligase ligand 2 (333 ?M) completely inhibits the proliferation of human umbilical vein endothelial cells (HUVECs). It inhibits VEGF- and FGF2-induced angiogenesis by 14% in a chicken chorioallantoic membrane (CAM) assay in utero when administered at a dose of 100 ?g/embryo.1
1.Marks, M.G., Shi, J., Fry, M.O., et al.Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferationBiol. Pharm. Bull.25(5)597-604(2002) 2.Robb, C.M., Contreras, J.I., Kour, S., et al.Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)Chem. Commun. (Camb.)53(54)7577-7580(2017) 3.Nakamura, T., Noguchi, T., Kobayashi, H., et al.Mono- and dihydroxylated metabolites of thalidomide: Synthesis and TNF-α production-inhibitory activityChem. Pharm. Bull. (Tokyo)54(12)1709-1714(2006)
| Cas No. | 5054-59-1 | SDF | |
| 别名 | 2-(2,6-二氧代-哌啶-3-基)-4-羟基-异吲哚-1,3-二酮,Cereblon ligand 2; E3 ligase Ligand 2 | ||
| Canonical SMILES | OC1=CC=CC(C(N2C3C(NC(CC3)=O)=O)=O)=C1C2=O | ||
| 分子式 | C13H10N2O5 | 分子量 | 274.23 |
| 溶解度 | DMSO : ≥ 36.5 mg/mL (133.10 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.6466 mL | 18.2329 mL | 36.4657 mL |
| 5 mM | 0.7293 mL | 3.6466 mL | 7.2931 mL |
| 10 mM | 0.3647 mL | 1.8233 mL | 3.6466 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet